Iovance Biotherapeutics Misses Q1 Profit Estimates, Operating Income Falls Short
IOVA has more than doubled off its 52-week low of $1.639.
Summary
Iovance Biotherapeutics reported Q1 revenue of $71.43 million, but significantly missed analyst estimates across key profitability metrics. The company posted an operating income of -$81.043 million, falling short of the IBES estimate of -$66.7 million. Similarly, pretax profit and net income also missed estimates, indicating a weaker-than-expected financial performance for the quarter. This news is likely to put downward pressure on the stock as it suggests the company is struggling to meet profitability expectations despite revenue generation. Traders will be watching for management commentary on the drivers of these misses and any revised outlook.
At the time of this announcement, IOVA was trading at $3.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $1.64 to $5.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.